Cart
sales@molnova.com
JAK-IN-21
CAS No. 2445499-20-5
JAK-IN-21( —— )
Catalog No. M35565 CAS No. 2445499-20-5
JAK-IN-21 is a selective and potent JAK inhibitor that inhibits JAK1, JAK2, J2V617F and TYK2 with IC50 values of 1.73, 2.04, 109 and 62.9 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 215 | In Stock |
|
| 10MG | 328 | In Stock |
|
| 25MG | 630 | In Stock |
|
| 50MG | 768 | In Stock |
|
| 100MG | 977 | In Stock |
|
| 200MG | 1283 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJAK-IN-21
-
NoteResearch use only, not for human use.
-
Brief DescriptionJAK-IN-21 is a selective and potent JAK inhibitor that inhibits JAK1, JAK2, J2V617F and TYK2 with IC50 values of 1.73, 2.04, 109 and 62.9 nM, respectively.
-
DescriptionJAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively.
-
In VitroJAK-IN-21 (Example 4) doses not inhibit CYPs and shows good liver microsome stability.
-
In VivoJAK-IN-21 (Example 4) shows low bioavailability (F=1.9%).Animal Model:SD rats Dosage:10 mg/kg Administration:Oral gavage (Pharmacokinetic Study).
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK | Tyrosine Kinases
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2445499-20-5
-
Formula Weight372.38
-
Molecular FormulaC19H16N8O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (335.68 mM; Ultrasonic )
-
SMILESCC=1C(=NC(NC2=CN(CC#N)N=C2)=NC1)C3=CC=C(C(NCC#N)=O)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PRN371
PRN371 is a novel potent, selective JAK3 inhibitor with IC50 of 0.5 nM.
-
PF-06651600
PF-06651600 is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2; inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models; selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β production in IL-27-primed macrophages.Rheumatoid ArthritisPhase 2 Clinical
-
BMS-986165
BMS-986165 is differentiated from previous JAK inhibitors due its unique ability to selectively bind to the pseudokinase (JH2) domain of TYK2 and inhibit its function through an allosteric mechanism.
